Phase I Clinical Trial of NIH 972 in Dogs with Spontaneously Occurring Sarcomas

Patient Disease:

Canine Sarcoma

Study Name:

Phase I Clinical Trial of NIH 972 in Dogs with Spontaneously Occurring Sarcomas

Purpose of the study:

  • To evaluate the safety and biologic effects of the novel drug NIH 972 in dogs with cancer
    • A secondary goal is to evaluate any anti-tumor effects it may have in dogs with sarcomas

Primary Eligibility Criteria:

  • Weight at least 10 kg (22 lb)
  • Histologically or cytologically confirmed diagnosis of sarcoma with evidence of expression of CD206 (will be determined prior to enrollment)
  • Adequate blood work
  • 3-week washout from chemotherapy, 6 weeks from radiation therapy, 72 hrs from steroids/immunosuppressive medications
  • Pets must come to CSU for all visits related to the clinical trial

Study Protocol:

  • Dogs will receive NIH 972 by mouth once daily
  • Serial blood sample collections for 8 hours after first dose; recheck visits at weeks 1, 2, 4, and 6 and then every 4 weeks for physical exam and lab work; tumor biopsies done prior to starting treatment and at week 2 visit

Owner Responsibilities:

  • You are responsible for the initial testing to determine study eligibility and any other tests recommended by your pet’s oncologist
  • You are expected to make and keep all appointments associated with the study
  • You must be comfortable administering oral medications to your dog daily and keeping a written log of drug administration and any side effects

Financial Incentives:

  • All costs related to the study including exam fees, drug dispensing, blood and urine monitoring, imaging if necessary to determine tumor size, and tumor biopsies will be covered by the clinical trial
  • There are also funds available to cover the costs of treatment of any side effects related to the study drug or procedures (up to $2000/event)
  • Participating owners will receive a $750 credit to their dog’s VTH account, which can be applied to the costs associated with initial testing if the dog qualifies for the study, or used to defray costs associated with other cancer treatment when the study is complete

If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.

flint animal cancer center newsletter

join our community

Be among the first to learn the latest Flint Animal Cancer Center news and pet cancer treatment information.
  • This field is for validation purposes and should be left unchanged.